Applied Therapeutics Stock Plummets After FDA Rejects Metabolic Disease Drug
1. FDA rejected Applied Therapeutics' application for govorestat in galactosemia. 2. Shares plummeted 75% following the FDA's Complete Response Letter. 3. CEO declared potential benefits of govorestat for patients, citing efficacy data. 4. The company plans to discuss resubmission or appeal with FDA.